Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience® (Mazindol ER) in the Treatment of Narcolepsy
